BROADCASTS.com

Published: Nov. 1, 2021, 8 a.m.

David Nutt is a psychiatrist and a neuroscientist at Downing College, Cambridge.\xa0\xa0His research focuses on illicit drugs\u2014their harm, classification, and potential for therapeutic use in psychiatry. In this episode, David discusses his framework for assessing the potential harm caused by common recreational drugs and explains how they are regulated, which is oftentimes misaligned with actual risk. He describes in detail the neurobiology, mechanisms of action, and addiction potential of alcohol, opiates, cocaine, and methamphetamine and contrasts those with psychedelics, which have been given a similar regulatory classification despite their relatively low risk of harm and their numerous potential therapeutic uses. Additionally, David explains the promise of psychedelics like ketamine, MDMA, and psilocybin for treating drug addiction and depression and discusses how political pressures have created roadblocks to future necessary research.

We discuss:

• David\u2019s early interest in the brain and experience in psychiatry [2:45];
  
• David\u2019s brief work on government drug policy in the UK [10:15];
  
• A scale for rating the relative harm of certain drugs [13:45];
  
• The contrast\xa0in regulation\xa0between cannabis vs. alcohol and\xa0why\xa0research on potential benefits of cannabis\xa0is lacking\xa0[19:15];
  
• The opiate crisis and rise of fentanyl: the cause and potential solution [25:00];
  
• The science of addiction and the potential use of psychedelics for treating drug addiction [35:00];
  
• Cocaine: mechanisms of action and risks [41:45];
  
• Methamphetamine and crystal meth: mechanisms of action and neurotoxicity [48:15];
  
• How psychedelics came to be classified as schedule I drugs despite their numerous therapeutic uses [52:45];
  
• The history of MDMA and the bad science and political forces leading to its demonization [1:08:45];
  
• History of ketamine, medical use of esketamine, and the\xa0waning\xa0effects of psychedelics with increasing usage [1:13:30];
  
• Psilocybin for depression: David\u2019s promising research and the roadblocks to more robust experiments [1:20:15];
  More.

Learn more:\xa0https://peterattiamd.com/
Show notes page for this episode: https://peterattiamd.com/davidnutt\xa0
Subscribe to receive exclusive subscriber-only content:\xa0 https://peterattiamd.com/subscribe/
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/
Connect with Peter on Facebook | Twitter | Instagram.